Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel.

Literature DB >> 34212838

Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel.

Yaniv Lustig^1,2, Neta Zuckerman², Ital Nemet², Nofar Atari², Limor Kliker², Gili Regev-Yochay^3,1, Einav Sapir^3,1, Orna Mor^1,2, Sharon Alroy-Preis⁴, Ella Mendelson^1,2, Michal Mandelboim^1,2.

Abstract

SARS-CoV-2 Delta (B.1.617.2) variant of concern (VOC) and other VOCs are spreading in Europe. Micro-neutralisation assays with sera obtained after Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in 36 healthcare workers (31 female) demonstrated significant fold change reduction in neutralising titres compared with the original virus: Gamma (P.1) 2.3, Beta (B.1.351) 10.4, Delta 2.1 and 2.6. The reduction of the Alpha (B.1.1.7) variant was not significant. Despite being lower, remaining neutralisation capacity conferred by Comirnaty against Delta and other VOCs is probably protective.

Entities: CellLine Chemical Disease Gene Mutation Species

Keywords: B.1.617.2 (Delta); BNT162b2 vaccination; COVID-19; neutralizing; variants

Year: 2021 PMID： 34212838 DOI： 10.2807/1560-7917.ES.2021.26.26.2100557

Source DB: PubMed Journal: Euro Surveill ISSN： 1025-496X

55 in total

Review 1. Two Years into the COVID-19 Pandemic: Lessons Learned.

Authors: Severino Jefferson Ribeiro da Silva; Jessica Catarine Frutuoso do Nascimento; Renata Pessôa Germano Mendes; Klarissa Miranda Guarines; Caroline Targino Alves da Silva; Poliana Gomes da Silva; Jurandy Júnior Ferraz de Magalhães; Justin R J Vigar; Abelardo Silva-Júnior; Alain Kohl; Keith Pardee; Lindomar Pena
Journal: ACS Infect Dis Date: 2022-08-08 Impact factor: 5.578

2. Immune Responses Against SARS-CoV-2 WT and Delta Variant in Elderly BNT162b2 Vaccinees.

Authors: Michael Jäger; Sissy Therese Sonnleitner; Stefanie Dichtl; Eliott Lafon; Gabriel Diem; Gernot Walder; Cornelia Lass-Flörl; Doris Wilflingseder; Wilfried Posch
Journal: Front Immunol Date: 2022-06-27 Impact factor: 8.786

3. Neutralizing Antibodies Response against SARS-CoV-2 Variants of Concern Elicited by Prior Infection or mRNA BNT162b2 Vaccination.

Authors: Floriana Bonura; Dario Genovese; Emanuele Amodio; Giuseppe Calamusa; Giuseppa Luisa Sanfilippo; Federica Cacioppo; Giovanni Maurizio Giammanco; Simona De Grazia; Donatella Ferraro
Journal: Vaccines (Basel) Date: 2022-05-30

4. Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity.

Authors: Carolina Lucas; Chantal B F Vogels; Inci Yildirim; Jessica E Rothman; Peiwen Lu; Valter Monteiro; Jeff R Gehlhausen; Melissa Campbell; Julio Silva; Alexandra Tabachnikova; Mario A Peña-Hernandez; M Catherine Muenker; Mallery I Breban; Joseph R Fauver; Subhasis Mohanty; Jiefang Huang; Albert C Shaw; Albert I Ko; Saad B Omer; Nathan D Grubaugh; Akiko Iwasaki
Journal: Nature Date: 2021-10-11 Impact factor: 69.504

5. A systematic review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant.

Authors: Mengxin Zhang; Ying Liang; Dongsheng Yu; Bang Du; Weyland Cheng; Lifeng Li; Zhidan Yu; Shuying Luo; Yaodong Zhang; Huanmin Wang; Xianwei Zhang; Wancun Zhang
Journal: Int J Biol Sci Date: 2022-01-01 Impact factor: 6.580

Review 6. VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants.

Authors: Wasim A Prates-Syed; Lorena C S Chaves; Karin P Crema; Larissa Vuitika; Aline Lira; Nelson Côrtes; Victor Kersten; Francisco E G Guimarães; Mohammad Sadraeian; Fernando L Barroso da Silva; Otávio Cabral-Marques; José A M Barbuto; Momtchilo Russo; Niels O S Câmara; Gustavo Cabral-Miranda
Journal: Vaccines (Basel) Date: 2021-11-30

7. Phage Display-Derived Peptide for the Specific Binding of SARS-CoV-2.

Authors: Fan Yang; Li Liu; Pierre Fernand Neuenschwander; Steven Idell; Ramakrishna Vankayalapati; Krishan Gopal Jain; Ke Du; Honglong Ji; Guohua Yi
Journal: ACS Omega Date: 2021-12-29

Review 8. Experimental Models of COVID-19.

Authors: Luis A Caldera-Crespo; Michael J Paidas; Sabita Roy; Carl I Schulman; Norma Sue Kenyon; Sylvia Daunert; Arumugam R Jayakumar
Journal: Front Cell Infect Microbiol Date: 2022-01-05 Impact factor: 5.293

9. Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Induced by Natural Infection or Vaccination: A Systematic Review and Pooled Analysis.

Authors: Xinhua Chen; Zhiyuan Chen; Andrew S Azman; Ruijia Sun; Wanying Lu; Nan Zheng; Jiaxin Zhou; Qianhui Wu; Xiaowei Deng; Zeyao Zhao; Xinghui Chen; Shijia Ge; Juan Yang; Daniel T Leung; Hongjie Yu
Journal: Clin Infect Dis Date: 2022-03-01 Impact factor: 20.999

10. Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants.

Authors: Ruiqi Zhang; Danlei Liu; Ka-Yi Leung; Yujing Fan; Lu Lu; Pui-Chun Chan; Kelvin Kai-Wang To; Honglin Chen; Kwok-Yung Yuen; Kwok-Hung Chan; Ivan Fan-Ngai Hung
Journal: Vaccines (Basel) Date: 2022-01-03